7 Real-World Evidence & Epidemiology CROs

What is Real-World Evidence and Epidemiology, and when do you need it in drug development?

Real-World Evidence (RWE) is clinical evidence about how a drug is used and how it performs, drawn from data generated outside a randomized trial. The raw material is real-world data: insurance claims, electronic health records, disease and product registries, patient-reported outcomes, pharmacy and lab feeds, sometimes wearable or mobile data. Epidemiology is the discipline that turns that messy observational data into a defensible answer, controlling for confounding, selection, and the fact that nobody was randomized. The two travel together, which is why sponsors usually source them as one service.

You reach for this work at several distinct points, and the study design changes completely depending on which one you are in. Early on, a natural-history or burden-of-illness study describes how a disease actually progresses and how many patients it touches, which feeds trial design, endpoint selection, and the case for a program. As you approach a trial, an external control arm or synthetic control built from real-world data can stand in for a placebo group in a rare disease or oncology setting where randomizing patients to placebo is not ethical or not feasible. After approval, the work shifts to post-marketing safety (FDA Sentinel-style surveillance, post-authorization safety studies the EMA may require), comparative effectiveness, and the health economics and outcomes research (HEOR) that payers want before they will reimburse.

The regulatory weight behind this has grown, which is the practical reason to take design seriously rather than treating RWE as a marketing exercise. The FDA's RWE framework under the 21st Century Cures Act, and guidance on fit-for-purpose data sources and study designs, mean a real-world study aimed at a label claim is held to a real standard. A registry analysis you commission to support an sNDA or a label expansion has to be pre-specified, transparent about its data provenance, and analyzed with methods (propensity scoring, target trial emulation, sensitivity analyses) that a reviewer will probe. Done well it can support an approval. Done loosely it is exploratory color, useful internally and ignored by regulators.

What does a Real-World Evidence and Epidemiology CRO actually do?

A capable RWE and epidemiology CRO sits between a question and a dataset, and most of the value is in getting the design and the data source right before a single analysis runs. The work usually starts with a feasibility and data-landscape assessment: which data sources can actually answer your question, do they have enough patients with your condition, do they capture the outcomes and covariates you need, and what is the lag and completeness of the feed. A claims database is good at utilization and cost but blind to lab values and disease severity. An EHR network sees clinical detail but may miss care delivered outside its system. Picking the wrong source is the most common and most expensive mistake, and a good vendor will talk you out of a source that cannot carry the study.

From there the deliverables are concrete. They write a study protocol and a statistical analysis plan, register the study where required (the EU PAS Register for European post-authorization work, ENCePP standards, or HMA/EMA catalogues), do the data acquisition and licensing, build the analytic cohort, and run the epidemiological analysis with the confounding-control methods the question demands. The output is a study report, often a manuscript for peer review, and increasingly an HEOR package (cost-effectiveness models, budget-impact models, value dossiers) for payer submissions. Specific designs you will hear named include retrospective cohort and case-control studies, prevalence and incidence estimates, treatment-pattern and adherence analyses, external control arms, and target trial emulation for causal questions.

How do you choose a Real-World Evidence and Epidemiology CRO?

The first filter is fit to your question and your therapeutic area, not the size of the database the vendor licenses. A shop that is excellent at large-population cardiometabolic claims analyses may have almost no signal in a rare disease where the relevant patients live in a single specialty registry. Match the vendor to the indication, the data type, and the decision the study has to support (internal go/no-go, an external control arm a regulator will scrutinize, or a payer dossier), because the bar and the right methods differ sharply across those.

Beyond fit, weigh the items below. The recurring theme is that observational research is only as trustworthy as the data behind it and the rigor of the methods, so a cheap study built on the wrong source or thin methods is the most expensive outcome there is.

• Quality and GxP posture: for safety and pharmacovigilance work expect GCP/GVP-aligned processes, GMA (Good Pharmacoepidemiology Practices) and ENCePP adherence, validated systems, audit trails, and a transparent inspection and audit history.
• Data access and fitness for purpose: what sources do they actually license or have rights to (claims, EHR, registries, tokenized linkages), how many relevant patients, what geography, and is the source fit for purpose for your specific question rather than just large.
• Methodological depth: real epidemiologists and biostatisticians on staff who can defend propensity scoring, target trial emulation, sensitivity and bias analyses, and negative-control work, not just SQL hands pulling counts.
• Capacity and lead time: data licensing and access can itself take weeks before any analysis starts, so confirm the queue, the data-acquisition timeline, and who the named lead epidemiologist is, in writing.
• Modality and indication fit: relevant experience in your disease area and patient population, with prior studies a regulator or payer accepted, especially for external control arms and label-expansion claims.
• Region and regulatory track record: a record with FDA RWE submissions, EMA post-authorization safety studies, EU PAS registration, and the specific HTA bodies (NICE, IQWiG, ICER) you plan to face.
• Data privacy, IP, and confidentiality: HIPAA, GDPR, and de-identification or tokenization handled correctly, with clear terms on who owns the study results, the analytic code, and any derived datasets.